



ASX ANNOUNCEMENT

Lumos Awarded National Contract with MediGroup for FebriDx®

MELBOURNE, Australia 25 September 2024 – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, has been awarded placement of their novel point-of-care test, FebriDx®, on the MediGroup national contract, making it available to all their members in the United States.

FebriDx is a rapid point-of-care respiratory test which delivers results in 10 minutes from a fingerstick blood sample. In July 2023, the US Food and Drug Administration cleared FebriDx to be marketed in the US as an aid in the diagnosis of bacterial acute respiratory infection and differentiation from non-bacterial etiology. The test has been cleared for use by healthcare professionals with patients presenting in urgent care or emergency care settings and is intended to be used in conjunction with clinical signs and symptoms, including other clinical and laboratory findings, to evaluate patients for acute respiratory infection.

MediGroup is the single largest non-acute care group purchasing organization (GPO) in the United States. MediGroup works alongside its sizable roster of members-which includes surgical clinics, non-acute care facilities and physician offices nationwide- and helps them cut annual costs by connecting them with only the very best services and products.

Lumos CEO and Managing Director, Doug Ward said, “We are very pleased to see FebriDx® added to MediGroup’s national contract. As a leading group purchasing organization, MediGroup has more than 30,000 members, including a mix of moderately complex labs and CLIA waived locations. This is a key relationship for us as we continue to build out our distribution coverage for FebriDx®.”

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Lumos - Media Contact:

Haley Chartres – Australia
H[^]CK Director
haley@hck.digital
+61 423 139 163

Lumos - Investor Contact:

Jane Lowe
Managing Director, IR Department
ir@lumosdiagnostics.com
+61 411 117 774

Lumos - Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205, Australia
+61 3 9087 1598